Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (71-80 of 301) with videos related to

Pageof 31
Sort By:
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
Blood Advances|September 30, 2024
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysisMohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, et al.
Leukemia & Lymphoma|November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Leukemia Research|May 3, 2005
Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survivalXavier Leleu, Franck Genevieve, Romain Guieze, et al.
Annals of Hematology|July 11, 2006
Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgensXavier Leleu, Louis Terriou, Alain Duhamel, et al.
American Journal of Hematology|August 18, 2020
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myelomaBrian G M Durie, Shaji K Kumar, Saad Z Usmani, et al.
British Journal of Haematology|October 16, 2014
Bendamustine is effective in T-cell prolymphocytic leukaemiaCharles Herbaux, Philippe Genet, Krimo Bouabdallah, et al.
Haematologica|August 16, 2023
Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysisThierry Facon, Philippe Moreau, Ross Baker, et al.
The American Journal of Medicine|August 31, 2010
Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imagingArsene Mekinian, Christophe Lions, Xavier Leleu, et al.
Haematologica|June 23, 2022
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMATom Martin, Paul G Richardson, Thierry Facon, et al.
Pageof 31

Showing results (71-80 of 301) with videos related to

Sort By:
Pageof 31
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
Blood Advances|September 30, 2024
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysisMohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, et al.
Leukemia & Lymphoma|November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Leukemia Research|May 3, 2005
Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survivalXavier Leleu, Franck Genevieve, Romain Guieze, et al.
Annals of Hematology|July 11, 2006
Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgensXavier Leleu, Louis Terriou, Alain Duhamel, et al.
American Journal of Hematology|August 18, 2020
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myelomaBrian G M Durie, Shaji K Kumar, Saad Z Usmani, et al.
British Journal of Haematology|October 16, 2014
Bendamustine is effective in T-cell prolymphocytic leukaemiaCharles Herbaux, Philippe Genet, Krimo Bouabdallah, et al.
Haematologica|August 16, 2023
Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysisThierry Facon, Philippe Moreau, Ross Baker, et al.
The American Journal of Medicine|August 31, 2010
Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imagingArsene Mekinian, Christophe Lions, Xavier Leleu, et al.
Haematologica|June 23, 2022
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMATom Martin, Paul G Richardson, Thierry Facon, et al.
Pageof 31